© 2020 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
CAR T-Cell Therapy
Integrating EMR Into the Clinical Management of CAR T-Cell Therapy Improves Patient Care
May 14, 2020
In an interview with Targeted Oncology, Andrea Price, APN, discussed the importance of integrating the electronic medical record team into the clinical care team for the treatment of patients with cancer receiving CAR T-cell therapy.
FDA Halts Review of BLA for Ide-cel in R/R Multiple Myeloma Pending Additional Data
May 13, 2020
The review of the Biologics License Application for idecabtagene vicleucel has been put on hold. The FDA issued a Refusal to File letter due to the need for additional data from the developer of the drug.
Protocol Management, Off-the-Shelf Therapies Help Bring CAR T Into More Settings
May 12, 2020
Relevant professional meetings and oncology publications exploded with research and news about chimeric antigen receptor T cells, and this cellular therapy strategy is now being explored across hematologic and solid malignancies.
Higher CAR T-Cell Dosage Improves Efficacy Without Toxicity in Relapsed or Refractory CLL
May 10, 2020
Patients with relapsed or refractory chronic lymphocytic leukemia who received a higher dose of CAR T cells, achieved complete responses, regardless of cell dose, which was highly correlated with long-term survival.
FDA Extends Target Action Date for Liso-cel in R/R Large B-cell Lymphoma
May 06, 2020
The FDA extended the Prescription Drug User Fee Act target action date for liso-cel due to the submission of additional information by the drug developer, which will require additional time to review.
Exploring the Current Role of CAR T Cells in Acute Lymphoblastic Leukemia
May 01, 2020
Jae Park, MD, discusses his key takeaways from chimeric antigen receptor T cells in the treatment landscape of patients with acute lymphoblastic leukemia.
Community Oncologists Critical to Success of CAR T-cell Therapy in R/R Large B-Cell Lymphoma
April 28, 2020
Few options exist for patients with relapsed or refractory large B-cell lymphomas who have already undergone 2 rounds of systemic therapy. New research shows axicabtagene ciloleucel might be a strong option, but community oncologists must play a role in patient identification and post-treatment follow-up.
Preparing Cancer Centers for Outpatient CAR T-cell Administration
April 23, 2020
David G. Maloney, MD, PhD, reviews the protocols and infrastructure necessary to deliver chimeric antigen receptor T-cell therapy to patients receiving treatment in the outpatient setting.
Evaluating the Feasibility of Liso-cel Administration in the Outpatient Setting
April 22, 2020
Carlos R. Bachier, MD, discusses how an analysis of 3 clinical trials evaluating the efficacy of lisocabtagene maraleucel demonstrated the feasibility of outpatient administration of chimeric antigen receptor T-cell therapy.
FDA Grants RMAT Designation to Tisagenlecleucel in R/R Follicular Lymphoma
April 22, 2020
“This designation supports the advancement of Kymriah, which could potentially address an unmet need in certain patients with follicular lymphoma, as we strive to reimagine medicine at Novartis. These patients are often faced with the burden of several years of various treatments as their disease continues to progress.”